Abstract
Objectives-To measure, in a service setting, the effect of magnetic resonance imaging on diagnosis, diagnostic certainty, and patient management in the neurosciences; to measure the cost per patient scanned; to estimate the marginal cost of imaging and compare this with its diagnostic impact; to measure changes in patients' quality of life; and to record the diagnostic pathway leading to magnetic resonance imaging.
Design-Controlled observational study using questionnaires on diagnosis and patient management before and after imaging. Detailed costing study. Quality of life questionnaires at the time of imaging and six months later. Diagnostic pathways extracted from medical records for a representative sample.
Setting-Regional superconducting 1.5 T magnetic resonance service.
Subjects-782 consecutive neuroscience patients referred by consultants for magnetic resonance imaging during June 1988-9;  diagnostic pathways recorded for 158 cases.
Main outcome measures-Costs of magnetic resonance imaging and preliminary investigations; changes in planned management and resulting savings; changes in principal diagnosis and diagnostic certainty; changes in patients' quality of life.
Results-Average cost of magnetic resonance imaging was estimated at £206. 20 Conclusions-Any improvement in diagnosis with magnetic resonance imaging is achieved at a higher cost. Techniques for monitoring the cost effectiveness of this technology need to be developed.
Introduction
Magnetic resonance imaging is recognised as a potentially useful,'16 although expensive,'-' imaging technique. Early evaluations of its clinical benefits have been criticised recently,'0-'2 and its clinical efficacy still has to be rigorously shown.13-16 Meanwhile, clinicians and managers are faced with decisions on when and how to introduce this new medical technology. '7 In 1988 the West Midlands region opened its first magnetic resonance imaging service, based in Coventry. It was expected that the main user would be the neurosciences, [18] [19] [20] and that demand would outstrip supply. Therefore, population based quotas were allocated to each of the region's four neuroscience centres. In addition, a service evaluation was commissioned to measure the extent to which magnetic resonance imaging in routine neuroscience clinical practice is worth its costs. As a result a large database has been built up and a full analysis is available elsewhere.2' This paper presents some of the findings of the study.
Methods
After a three month learning period we entered into the study all 782 patients scanned by the service as part of the NHS quota during the service's first year of operation. The imager is superconducting and runs at lST. (11) of spinal imaging for neurosurgery. Almost a fifth of 26(6) 78 (24) 11 (2) 40 (8) 67 (13) 103 (20) 132 (26) 94 (18) 44 (9) 20 (4) 14 (3) 34 (8) 49 (12) 80 (19) 92 (22) 90 (21) 50 (12) 8 (2) 3 (<1) 1 (<I) 25 (3) 74 (8) 117 (13) 183 (20) 225 (24) 186 (20) 94 (10) 28 (3) 3 (<1) 1 (<1) 647 (4) 1617 (10) 2427 (15) 3074 (19) 3074 (19) 2264 (14) 1941 (12) 971 (6) 162 (1) *Australia 49% female; Coventry 54% female.
scan the quality of life score fell, with the average score decreasing by 0 059 to 0-845. This was predicted by consultants at the time of referral (no change or don't know for 547 (70%) patients, slight deterioration for 164 (2 1%), and some improvement for 40 (5%)).
REPORTED INCREASES IN ACCURACY
The principal benefits predicted by radiologists were increased accuracy in identification (368 (47%) scans), determining the extent (110 (14%)), and location (39 (5%)) of disease and other benefits (23 (3%)); for 242 (31%) scans no benefit was identified. Examination shows that when increased accuracy in assessing the extent of the disease was expected, radiologists reported 88% (97) of scans delivered this; when increased accuracy in location was predicted, 82% (32) of scans delivered this; but when improved identification was expected only 45% (166) of scan delivered this.
IMPACT ON DIAGNOSIS
A change in diagnosis was reported in 159 cases (20% of referrals). In 107 the change was major, with a shift in categories; table IV gives the diagnoses before magnetic resonance imaging. Of those patients with unknown and "other, physical" diagnoses, 27 had the diagnosis changed after imaging. Nevertheless, the number of patients with an unknown diagnosis increased from 44 to 59 overall. Twelve patients with unknown diagnoses had their condition classified, but 27 with a provisional diagnosis were reclassified as having an unknown diagnosis after the scan. The overall number of patients with a diagnosis of "other, physical" did not change. Change in diagnosis was associated with an increase in diagnostic certainty; the mean value of the distribution rising from 66% to (2) 43 (5) 150 (19) 45 (6) 108 (14) 3 (< 1) 100 (13) 44 (6) 51 (7) 1(<1) 142 (18) 782 (100) 87 5% (excluding diagnosis unknown). In a further 236 (30%) cases diagnostic confidence was increased.
IMPACT ON PATIENT MANAGEMENT
Changes in management were reported in 208 (27%) cases. Eleven of 138 proposed operations were abandoned. Three procedures were deferred, three replaced by radiotherapy, and two patients were transferred to other surgeons or hospitals for surgery. In six cases the surgical approach was changed and in a further 11 it was made more precise. Twenty five myelograms, 21 computed tomograms, and three angiograms were abandoned. In a further 226 (29%) cases confidence in planned management was increased.28 Table V shows the relation between the impact of magnetic resonance imaging on diagnosis and that on patient management; changes in the two were closely, but not exclusively, linked. 
Discussion
Our evaluation highlights the tensions between ensuring maximum clinical impact and minimising overall costs. To use magnetic resonance imaging most effectively in "a situation where restriction seems necessary"29 it might be argued that patients need to be thoroughly investigated by conventional techniques before they are referred for magnetic resonance imaging. But by doing this some of the savings that could be realised through displacing these earlier procedures will be lost and the total costs of investigation may prove unnecessarily high. However, using magnetic resonance imaging too early in the diagnostic pathway may also not be cost effective if the most suitable patients are not correctly identified. In this instance effects on patient management will be less common and any consequent cost savings lower. It cannot be cost effective for expensive magnetic resonance imaging to be substituted for less expensive techniques if there is little or no difference in diagnostic efficacy unless there are sufficiently large benefits in patient safety or comfort.
We found that the diagnosis was altered in 20% of cases after magnetic resonance imaging. This is a similar level to that recently reported elsewhere in Britain.'6 Management was changed in 27% of cases, lower than in the recent British study,'6 but in a further 29% of cases conifidence in management increased. We estimated that management changes reduced the cost of imaging from £206.20 (including contrast media and upgrading costs) to a marginal cost of £125.30 per patient. There was no indication that patients' quality of life improved after magnetic resonance imaging; this agrees with the other British study. 16 The West Midlands population could support five magnetic resonance imaging units.293' If provided, the resulting marginal cost to the region would be about £1-4 million a year at 1989-90 prices, assuming that similarly high effects on patient management are maintained in all centres and all specialties (for example, orthopaedics). In the service setting, therefore, it seems that although magnetic resonance imaging can improve diagnosis this is achieved only at a higher overall cost.
One possible strategy to improve cost effectiveness would be to reduce the use of other radiographic procedures in the run up to magnetic resonance imaging. The diagnostic pathway information shows that in the neurosciences magnetic resonance imaging was used as an add on test and that invasive procedures such as myelography and combined computed tomography and myelography were often used before magnetic resonance imaging. If half of these procedures had been displaced this would have reduced the marginal cost (£125.30) by £62.20 per patient (including the cQst of admission to hospital). However, this might result in a larger number of inappropriate patients having magnetic resonance imaging.
If the costs of investigating patients cannot be reduced sufficiently to make the marginal cost of magnetic resonance imaging zero and patients' quality of life is not improved, the question which next needs to be asked is: What additional benefits does magnetic resonance imaging provide in terms of diagnostic impact which might be set against these costs? One way of describing this is in terms of the marginal cost per diagnostic change28; this was calculated to be £626 (for a marginal magnetic resonance imaging cost of £125). Although 29 of these diagnostic changes were moves from a provisional diagnosis to diagnosis unknown, the overall increase in patients with unknown diagnosis (5*5% to 7-5%) was substantially less than that reported in a recent study where magnetic resonance imaging was used as a first line diagnostic procedure (3% to 27%). This effect might therefore be limited by more extensive radiographic investigation before magnetic resonance imaging.
Even after implementing a series of controls (setting quotas, introducing a structured request form, and restricting referral to consultants) it has not proved possible to introduce a magnetic resonance imaging service for the neurosciences at zero cost. It is imperative for clinicians and managers to audit further use of this expensive imaging procedure, perhaps using a management systems approach.32 Even if minimisation of costs is the prime objective systematic monitoring is required of the degree to which cost savings from changes in patient management are maximised and costs of other investigations used in the diagnostic pathway are minimised.
Introduction
Intensified insulin treatment retards the development of microvascular diabetic complications at the expense of increasing the frequency of serious hypoglycaemic episodes.' After three years of intensified conventional treatment the hypoglycaemic episodes had not caused any permanent cortical dysfunction,2 although earlier studies found that patients with serious hypoglycaemia showed neuropsychological deficits.3-5 These studies, however, were either non-randomised or cross sectional and retrospective. (27/25) 16-1 (0-7) 31 6 (1-0) 0-75 (0-03) 22-8 (0-4) To clarify the long term effects of episodic hypoglycaemia on the brain has been suggested as a major scientific task. 6 We report the results of computerised neuropsychological tests after five years in patients randomised to intensified conventional insulin treatment or standard treatment.
Patients and methods
One hundred and two patients were selected for entry to the study, and after five years 96 patients remained in the study.' Five patients had died and one had moved away from Stockholm. The patients initially had insulin dependent diabetes, non-proliferative retinopathy, and unsatisfactory blood glucose control, as already described.' They were randomised to intensified conventional treatment (n=48 at entry and 44 after five years) or standard treatment (n=54 at entry and 52 after five years). The treatment regimens have been described.7 The groups were similar with regard to sex distribution, age, duration of diabetes, insulin dose, body mass index (table I) , smoking habits, alcohol consumption, and initial microvascular complications. ' After three years an effort was made to reduce glycated haemoglobin concentration below 9% in all the patients given regular treatment as nephropathy had been shown to increase steeply with higher concentrations.8 Two patients receiving standard treatment could not participate in the neuropsychological tests after fiveyears because of reduced visual acuity.
Glycated haemoglobin concentration (normal range 3-9-5 7%) was measured as described previously' 7 and the numbers of serious hypoglycaemic episodes (during which the patient required help from someone else) and episodes of unconsciousness were carefully recorded and reported by the patients at each office visit. ' 
